CN103917236A - 治疗增生性疾病的方法 - Google Patents
治疗增生性疾病的方法 Download PDFInfo
- Publication number
- CN103917236A CN103917236A CN201280054663.0A CN201280054663A CN103917236A CN 103917236 A CN103917236 A CN 103917236A CN 201280054663 A CN201280054663 A CN 201280054663A CN 103917236 A CN103917236 A CN 103917236A
- Authority
- CN
- China
- Prior art keywords
- braf
- proliferative disease
- raf
- inhibitor
- braf inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及用丝氨酸/苏氨酸激酶抑制剂治疗患者的方法,其中通过间歇给药方案给予丝氨酸/苏氨酸激酶抑制剂来抑制对丝氨酸/苏氨酸激酶抑制剂治疗的抗性。
Description
发明内容
本发明涉及抑制对BRAF抑制剂治疗抗性的方法。
发明背景
已熟知激酶参与增生性疾病。例如,肿瘤发生相关激酶包括受体酪氨酸激酶和丝氨酸/苏氨酸激酶、Raf激酶。这些激酶在影响和调节许多细胞功能,如增殖、分化和存活,的信号转导通路中起关键作用。
开发治疗增生性疾病的疗法仍是一项艰巨挑战。不断需要改善的治疗方法,特别是考虑到癌细胞在其生长和存活基本机制、其对治疗剂的应答、以及其突变并变得对所述试剂有耐性或抗性的能力方面而言的许多变化。
Raf激酶是促分裂原活化蛋白激酶(MAPK)信号通路的一部分,包括Ras-Raf-MEK1-ERK信号分子。Raf具有三个不同的同种型,即A-Raf、B-Raf和C-Raf,由其与上游调节因子Ras相互作用的能力来区分。Ras基因之一的激活突变可在约20%的所有肿瘤中观察到,且Ras/Raf/MEK/ERK通路在约30%的所有肿瘤中被激活(Bos等,Cancer Res.49:4682-4689,1989;Hoshino等,Oncogene18:813-822,1999)。B-Raf激酶结构域中的激活突变发生于约66%黑素瘤、12%结肠癌和14%肝癌中(Davies等,Nature417:949-954,2002;Yuen等,Cancer Research62:6451-6455,2002;Brose等,Cancer Research62:6997-7000,2002)。
小分子RAF抑制剂,如威罗菲尼,已证实了以下概念验证(proof-of-concept):BRAFV600E是黑素瘤增殖和生存的关键驱动因子,如晚期临床试验中患者的肿瘤消退和生存延长所证明。不幸的是,当迅速发展出RAF抑制剂抗性时,所述肿瘤反应短暂。
附图说明
图1.连续和间歇给药式II的BRAF抑制剂的比较,显示通过间歇给药对耐药细胞的生长优势的去除延迟或防止对BRAF抑制剂的抗性的发生。
发明详述
本发明基于以下发现:Raf激酶耐受肿瘤细胞‘适应性低于’Raf激酶抑制剂敏感性肿瘤细胞且在没有Raf激酶抑制剂情况下相比敏感细胞有选择劣势。因此,根据本发明,以间歇给药方案给予Raf激酶抑制剂可抑制对Raf激酶抑制剂治疗的抗性。
抑制对治疗的抗性指延迟或防止对Raf激酶抑制剂治疗抗性的发生。
本申请中,间歇给药方案指B-Raf激酶抑制剂进行一段时间给药,随后的一段时间暂停用B-Raf激酶抑制剂治疗。例如,Raf激酶抑制剂持续4周每天给药,之后的2周不治疗,并且在患者使用Raf激酶抑制剂治疗期间重复该循环。
BRAF抑制剂和其在治疗增生性疾病中的应用是本领域已知的。
威罗菲尼(PLX4032)是FDA批准用于治疗黑素瘤患者的BRAF抑制剂,所述患者的肿瘤表达BRAF V600E突变。威罗菲尼具有以下化学结构:
抑制MAPK通路中特定激酶的另一类化合物是苯并咪唑基吡啶基醚。美国专利7,482,367公开了式I的B-RAF激酶抑制剂,所述专利通过引用全文纳入本文。
抑制MAPK通路中特定激酶的另一类化合物是吡唑嘧啶。WO2011/025927通过引用全文纳入本文,其公开了作为BRAF激酶,尤其是带有BRAFV600E突变的BRAF激酶,的抑制剂的式II化合物:
本方法中,所述BRAF抑制剂优选是式II的化合物。
在设计用于测量BRAF抑制剂抗性出现的早期传代原发性人黑素瘤移植瘤模型中,我们确定了用BRAF抑制剂以临床相关剂量通过长期连续给药方案治疗移植瘤导致耐药性肿瘤在4-6周过程中出现。个体肿瘤内的药效动力学(PD)分析表明,RAF-MEK-ERK通路在耐药性肿瘤中仍受抑制,尽管抑制程度和持续时间小于敏感性肿瘤。此外,通路抑制和恢复的动力学在各耐药性肿瘤间有所不同。生化分析表明丝氨酸/苏氨酸激酶和丝氨酸/苏氨酸激酶负反馈环的调节可能参与耐药性、以及BRAF V600E表达上调。肿瘤应答的药理评价为肿瘤细胞群和耐药性进化提供见解。增加给予荷耐药性瘤小鼠的药物剂量导致显著但短暂的肿瘤反应,然后是肿瘤发展。综合PD数据,可以得出合理的结论,即存在大量肿瘤细胞异质性,且肿瘤能迅速适应因给药而施加的选择压力。通过中止对移植有耐药性小鼠的治疗得到了支持该结论的进一步证据。停药后,肿瘤起初在数天到数周内消退,之后再生长。这些数据表明,在处于选择压力下的肿瘤细胞群内出现的适应性使得所述细胞较为不适应药物缺乏的情况。
所有耐药性肿瘤在BRAF抑制剂化合物存在情况下具有的p-ERK水平高于敏感性肿瘤且给药后的恢复速率更快。耐药性肿瘤之间的恢复动力学可变。BRAF耐药性肿瘤取决于用于生长的药物存在和导致肿瘤消退的药物移除。缺乏化合物时,耐药细胞的适应性低于敏感细胞。本发明利用此发现以通过间歇给药方案给予BRAF抑制剂来抑制对BRAF抑制剂治疗的抗性。
因此,本发明包括治疗增生性疾病的方法,所述方法包括通过间歇给药方案给予BRAF激酶抑制剂来抑制对BRAF激酶抑制剂治疗的抗性。
本发明特定包括治疗其特征在于BRAF激酶突变的增生性疾病的方法,所述方法包括通过间歇给药方案给予式II的BRAF抑制剂来抑制对式II的BRAF抑制剂治疗的抗性。
在一个优选实施方式中,本发明还涉及治疗特征为BRAF激酶突变的增生性疾病的方法,所述方法包括通过间歇给药方案给予BRAF抑制剂来抑制对BRAF抑制剂治疗的抗性。
本发明的此方面还涉及一种方法,其中BRAF突变是V600突变,如BRAFV600E。
由本发明方法治疗的增生性疾病包括癌症,例如但不限于,膀胱癌、乳腺癌、脑癌、头颈癌、肝癌、胆道癌、癌、急性和慢性淋巴细胞白血病、急性和慢性髓细胞性白血病、慢性骨髓单核细胞性白血病、结直肠癌、胃癌、胃肠道间质瘤、胶质瘤、淋巴瘤、黑素瘤、多发性骨髓瘤、骨髓及外骨髓增生性疾病、神经内分泌癌、肺癌、胰腺癌、卵巢癌、前列腺癌、肾细胞癌、肉瘤和甲状腺癌,如甲状腺乳头状癌。其他增生性疾病包括肥大细胞白血病、生殖细胞瘤、小细胞肺癌、胃肠道间质瘤、成神经细胞瘤和骨肉瘤。
更特定地,由本发明方法治疗的增生性疾病是特征为V600突变如BRAFV600E,的黑素瘤,或特征为V600突变如BRAFV600E的结直肠癌。
在一个重要的方面,所述间歇给药方案包括给予BRAF抑制剂持续4周,之后的2周时间不治疗,并在患者用BRAF抑制剂治疗时或者直到出现耐药性时重复所述循环。然而,其它间歇给药方案包括,例如,1周给药1周停药,2周给药1或2周停药,3周给药1、2或3周停药,4周给药1、2、3或4周停药,特别是4周给药1周停药或4周给药2周停药,5周给药1、2、3、4、或5周停药,6周给药1、2、3、4、5、或6周停药,等循环。
本发明还包括BRAF抑制剂在制备用于治疗增生性疾病的药物中的用途,其中所述BRAF抑制剂以间歇给药方案给予。特别地,式II的BRAF抑制剂用于制备治疗增生性疾病的药物,其中式II的BRAF抑制剂以间歇给药方案给予。
以下实施例描述本发明。
实施例1
将第3代Hmex1906原发性人黑素瘤植入裸鼠。监控小鼠,直到植入的肿瘤达到200-400mm3。一旦达到该尺寸,向小鼠一天两次给药5mg/kg Raf抑制剂(式II的化合物),持续4周。一些小鼠继续治疗,而另一些接受4周治疗2周停药的间歇治疗方案。
结果示于图1。所有连续接受式II化合物的小鼠均出现耐药性,但没有证据显示接受间歇给药方案的小鼠出现耐药性。
Claims (5)
1.一种治疗特征为BRAF激酶突变的增生性疾病的方法,所述方法包括通过间歇给药方案给予式II的BRAF抑制剂来抑制对式II的BRAF抑制剂治疗的抗性。
2.如权利要求1所述的方法,其中所述BRAF突变是V600突变。
3.如权利要求1所述的方法,其中所述增生性疾病是特征为V600突变的黑素瘤,或特征为V600突变的结直肠癌。
4.如权利要求1所述的方法,其特征在于,所述增生性疾病是特征为BRAFV600E的黑素瘤,或特征为BRAFV600E的结直肠癌。
5.式II的BRAF抑制剂
在制备用于治疗增生性疾病的药物中的用途,其中所述BRAF抑制剂以间歇给药方案给予。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810135736.8A CN108542906A (zh) | 2011-11-11 | 2012-11-09 | 治疗增生性疾病的方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161558619P | 2011-11-11 | 2011-11-11 | |
US61/558,619 | 2011-11-11 | ||
PCT/US2012/064269 WO2013070996A1 (en) | 2011-11-11 | 2012-11-09 | Method of treating a proliferative disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810135736.8A Division CN108542906A (zh) | 2011-11-11 | 2012-11-09 | 治疗增生性疾病的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103917236A true CN103917236A (zh) | 2014-07-09 |
Family
ID=47279036
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810135736.8A Pending CN108542906A (zh) | 2011-11-11 | 2012-11-09 | 治疗增生性疾病的方法 |
CN201280054663.0A Pending CN103917236A (zh) | 2011-11-11 | 2012-11-09 | 治疗增生性疾病的方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810135736.8A Pending CN108542906A (zh) | 2011-11-11 | 2012-11-09 | 治疗增生性疾病的方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11007194B2 (zh) |
EP (1) | EP2776037B1 (zh) |
JP (1) | JP6150813B2 (zh) |
CN (2) | CN108542906A (zh) |
AU (1) | AU2012335663B2 (zh) |
BR (1) | BR112014011223A8 (zh) |
CA (1) | CA2855243C (zh) |
HK (1) | HK1198920A1 (zh) |
MX (1) | MX354725B (zh) |
RU (1) | RU2622015C2 (zh) |
WO (1) | WO2013070996A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110256408A (zh) * | 2018-07-12 | 2019-09-20 | 深圳市塔吉瑞生物医药有限公司 | 一种二芳基吡唑化合物及包含该化合物的组合物及其用途 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
SI2882440T1 (sl) * | 2012-08-07 | 2019-05-31 | Novartis Ag | Farmacevtske kombinacije, ki vsebujejo inhibitor B-RAF, inhibitor EGFR in neobvezno inhibitor PI3K-alfa |
SG11201810793XA (en) | 2016-06-03 | 2018-12-28 | Giordano Caponigro | Pharmaceutical combinations |
US11590133B2 (en) * | 2016-12-11 | 2023-02-28 | Memorial Sloan Kettering Cancer Center | Methods and compositions for treatment of BRAF mutant cancers |
TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療braf相關的疾病和失調症之化合物 |
WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011025927A1 (en) * | 2009-08-28 | 2011-03-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US6037136A (en) | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
SK157899A3 (en) | 1997-05-22 | 2000-08-14 | Searle & Co | Substituted pyrazoles as p38 kinase inhibitors, process for their preparation and pharmaceutical compositions |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6204467B1 (en) | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
ME00275B (me) | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
US6316435B2 (en) | 1999-02-24 | 2001-11-13 | Supergen, Inc. | Combination therapy for lymphoproliferative diseases |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
IL161462A0 (en) | 2001-10-25 | 2004-09-27 | Novartis Ag | Combinations comprising a selective cyclooxygenase-2 inhibitor |
WO2003055860A1 (en) | 2001-12-21 | 2003-07-10 | Vernalis (Cambridge) Limited | 3,4-diarylpyrazoles and their use in the therapy of cancer |
WO2005027972A2 (en) | 2003-09-23 | 2005-03-31 | Novartis Ag | Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
DK1692113T3 (en) | 2003-11-14 | 2018-01-08 | Lorus Therapeutics Inc | ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES |
CA2551948A1 (en) | 2004-01-09 | 2005-07-28 | Novartis Ag | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors |
US7745437B2 (en) | 2004-06-10 | 2010-06-29 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
CA2601766A1 (en) | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
US20070099856A1 (en) * | 2005-05-13 | 2007-05-03 | Gumerlock Paul H | Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen |
CA2618377A1 (en) | 2005-08-12 | 2007-02-22 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate hsp90 activity |
BRPI0614870A2 (pt) | 2005-08-22 | 2011-04-19 | Novartis Ag | composições farmacêuticas |
EP1917258A2 (en) | 2005-08-26 | 2008-05-07 | SmithKline Beecham Corporation | Pyrimidinyl-pyrazole inhibitors of aurora kinases |
TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
CA2643066A1 (en) | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazole compounds |
AU2007234379A1 (en) | 2006-04-05 | 2007-10-11 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
US7501430B2 (en) | 2006-04-17 | 2009-03-10 | Arqule, Inc. | RAF inhibitors and their uses |
US8202876B2 (en) | 2006-10-02 | 2012-06-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US20100087464A1 (en) | 2006-10-06 | 2010-04-08 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
RU2009134223A (ru) | 2007-02-15 | 2011-03-20 | Новартис АГ (CH) | Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака |
US20090022789A1 (en) | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
EA201000113A1 (ru) | 2007-08-01 | 2010-08-30 | Пфайзер Инк. | Пиразольные соединения |
MX2010004291A (es) | 2007-10-19 | 2010-08-02 | Abbott Gmbh & Co Kg | Producto de dispersion solida de farmacos basados en n-aril urea. |
JP5433582B2 (ja) | 2007-11-14 | 2014-03-05 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | イミダゾ[1,2−a]ピリジン誘導体およびmGluR2受容体の正のアロステリック調節因子としてのその使用 |
MX2010010317A (es) | 2008-03-21 | 2010-10-04 | Novartis Ag | Compuestos heterociclicos novedosos y usos de los mismos. |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
PT2324008E (pt) | 2008-07-24 | 2012-06-25 | Nerviano Medical Sciences Srl | 3,4-diarilpirazoles como inibidores da proteína quinase |
CN102123987A (zh) | 2008-07-28 | 2011-07-13 | 吉里德科学公司 | 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物 |
PE20110294A1 (es) | 2008-09-29 | 2011-05-26 | Boehringer Ingelheim Int | Compuestos heterociclicos como inhibidores de enzimas de senal especifica |
CN102238945B (zh) | 2008-10-07 | 2014-10-29 | 阿斯利康(英国)有限公司 | 药物制剂514 |
US20110293750A1 (en) | 2008-11-11 | 2011-12-01 | Yale University | Activated wnt-beta-catenin signaling in melanoma |
EP2373664B1 (en) | 2008-12-19 | 2013-06-12 | Nerviano Medical Sciences S.r.l. | Bicyclic pyrazoles as protein kinase inhibitors |
AR075180A1 (es) | 2009-01-29 | 2011-03-16 | Novartis Ag | Formulaciones orales solidas de una pirido-pirimidinona |
RU2402602C1 (ru) * | 2009-02-12 | 2010-10-27 | Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН | КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН |
WO2010100127A1 (en) | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
TWI532484B (zh) | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
EP2443117B1 (en) | 2009-06-15 | 2016-03-23 | Nerviano Medical Sciences S.r.l. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
US8791265B2 (en) | 2010-01-27 | 2014-07-29 | Nerviano Medical Sciences S.R.L. | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
CA2829790C (en) | 2010-03-30 | 2018-06-05 | Verseon Corporation | Multisubstituted aromatic compounds as inhibitors of thrombin |
US9114137B2 (en) | 2010-08-03 | 2015-08-25 | Nerviano Medical Sciences S.R.L. | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
JP5999724B2 (ja) | 2011-03-21 | 2016-09-28 | ヴァルキュリア アクチアボラグValcuria AB | Hdac阻害剤及びステロイドを含む医薬組成物及びその使用 |
CN103608012A (zh) | 2011-06-14 | 2014-02-26 | 诺华股份有限公司 | 在癌症如骨髓增殖性肿瘤治疗中的帕比司他与鲁索利替尼的组合 |
LT2782557T (lt) | 2011-11-23 | 2018-12-27 | Array Biopharma, Inc. | Farmacinės kompozicijos |
US20150283136A1 (en) | 2012-11-08 | 2015-10-08 | Novartis Ag | Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
-
2012
- 2012-11-09 CA CA2855243A patent/CA2855243C/en active Active
- 2012-11-09 BR BR112014011223A patent/BR112014011223A8/pt not_active Application Discontinuation
- 2012-11-09 MX MX2014005726A patent/MX354725B/es active IP Right Grant
- 2012-11-09 CN CN201810135736.8A patent/CN108542906A/zh active Pending
- 2012-11-09 AU AU2012335663A patent/AU2012335663B2/en active Active
- 2012-11-09 WO PCT/US2012/064269 patent/WO2013070996A1/en active Application Filing
- 2012-11-09 JP JP2014541283A patent/JP6150813B2/ja active Active
- 2012-11-09 US US14/355,903 patent/US11007194B2/en active Active
- 2012-11-09 RU RU2014117707A patent/RU2622015C2/ru active
- 2012-11-09 CN CN201280054663.0A patent/CN103917236A/zh active Pending
- 2012-11-09 EP EP12795175.4A patent/EP2776037B1/en active Active
-
2014
- 2014-12-10 HK HK14112437.0A patent/HK1198920A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011025927A1 (en) * | 2009-08-28 | 2011-03-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110256408A (zh) * | 2018-07-12 | 2019-09-20 | 深圳市塔吉瑞生物医药有限公司 | 一种二芳基吡唑化合物及包含该化合物的组合物及其用途 |
WO2020011141A1 (zh) * | 2018-07-12 | 2020-01-16 | 深圳市塔吉瑞生物医药有限公司 | 一种二芳基吡唑化合物及包含该化合物的组合物及其用途 |
CN110256408B (zh) * | 2018-07-12 | 2022-03-22 | 深圳市塔吉瑞生物医药有限公司 | 一种二芳基吡唑化合物及包含该化合物的组合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
RU2014117707A (ru) | 2015-12-20 |
US20140275136A1 (en) | 2014-09-18 |
EP2776037A1 (en) | 2014-09-17 |
CN108542906A (zh) | 2018-09-18 |
WO2013070996A1 (en) | 2013-05-16 |
BR112014011223A2 (pt) | 2017-05-09 |
CA2855243A1 (en) | 2013-05-16 |
RU2622015C2 (ru) | 2017-06-08 |
US11007194B2 (en) | 2021-05-18 |
JP6150813B2 (ja) | 2017-06-21 |
MX354725B (es) | 2018-03-16 |
AU2012335663B2 (en) | 2015-12-24 |
MX2014005726A (es) | 2014-05-28 |
BR112014011223A8 (pt) | 2023-01-31 |
HK1198920A1 (zh) | 2015-06-19 |
JP2014533272A (ja) | 2014-12-11 |
CA2855243C (en) | 2020-04-14 |
AU2012335663A1 (en) | 2014-05-29 |
EP2776037B1 (en) | 2019-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103917236A (zh) | 治疗增生性疾病的方法 | |
Köhler et al. | Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review | |
Lin et al. | EGFR-TKI resistance in NSCLC patients: mechanisms and strategies | |
Furukawa | Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside | |
Bang et al. | Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts | |
Vakiani et al. | KRAS and BRAF: drug targets and predictive biomarkers | |
Martinelli et al. | Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells | |
Zhang et al. | Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer | |
Lu et al. | Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance | |
Imyanitov et al. | Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation | |
Hirohata et al. | Treatment of pituitary carcinomas and atypical pituitary adenomas: a review | |
Schubert et al. | Novel human-derived RET fusion NSCLC cell lines have heterogeneous responses to RET inhibitors and differential regulation of downstream signaling | |
Czejka et al. | Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer | |
KR20120099217A (ko) | 조합물 | |
CN109922804B (zh) | Fgfr4抑制剂和胆汁酸螯合剂的组合 | |
Squillante et al. | Targeted therapies in germ cell tumors | |
Kanat et al. | Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations | |
Girard | Targeted therapies for thymic malignancies | |
Raghavan | Chemotherapy for invasive bladder cancer: Five simple rules learned over 30 years | |
Tuna et al. | Activating mutations and targeted therapy in cancer | |
Li et al. | Cetuximab Combined with Vemurafenib Can Significantly Inhibit the Proli-Feration Of Braf V600e Mutant Egfr Wild-Type Colorectal Cancer Cells | |
Ikushima et al. | Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report | |
Daughety et al. | Regorafenib for treatment of imatinib-and sunitinib-resistant metastatic gastrointestinal stromal tumors | |
Ahluwalia et al. | Role of tyrosine kinase inhibitors in the management of high-grade gliomas | |
Ahn | Molecular targeted therapy in lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140709 |